[go: up one dir, main page]

PE20201150A1 - Composiciones farmaceuticas inyectables de isoxazolina y usos de las mismas - Google Patents

Composiciones farmaceuticas inyectables de isoxazolina y usos de las mismas

Info

Publication number
PE20201150A1
PE20201150A1 PE2020000593A PE2020000593A PE20201150A1 PE 20201150 A1 PE20201150 A1 PE 20201150A1 PE 2020000593 A PE2020000593 A PE 2020000593A PE 2020000593 A PE2020000593 A PE 2020000593A PE 20201150 A1 PE20201150 A1 PE 20201150A1
Authority
PE
Peru
Prior art keywords
isoxazoline
present
compound
haloalkyl
microns
Prior art date
Application number
PE2020000593A
Other languages
English (en)
Inventor
Keith A Freehauf
Brian Carrillo
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74717047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20201150(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of PE20201150A1 publication Critical patent/PE20201150A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/80—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se refiere a una composicion farmaceutica inyectable que comprende: a) particulas de un compuesto de isoxazolina de formula (I), donde: R1 es halogeno, CF3, OCF3 CN; n es 0 a 3; R2 es haloalquilo C1-C3, CF3 o CF2Cl; T es un anillo de 5 o 6 miembros, opcionalmente sustituido por Y, donde Y es metilo, halometilo, halogeno, entre otros; Q es X-NR3R4, NR5-NR6-X-R3, entre otros; X es CH2, CH(CH3), entre otros; R3 es hidrogeno, metilo, haloetilo, entre otros; R4 es hidrogeno, etilo, metoximetilo, entre otros; R5 y R6 son H, alquilo o haloalquilo, y b) un excipiente farmaceuticamente aceptable; en donde el compuesto de isoxazolina tiene una distribucion de tamano de particula ponderada en volumen D50 de 50 micras a 150 micras. Un compuesto de isoxazolina preferido es fluralaner, presente en una cantidad entre 5% p/v a 50% p/v; adicionalmente, dicha composicion comprende un compuesto parasiticida, tal como milbemicina o moxidectina, presente en una cantidad entre 0.1% p/v a 1.0% p/v. Tambien se refiere a un kit. Dicha composicion inyectable de isoxazolina presenta eficacia a largo plazo contra parasitos y un riesgo reducido de irritacion en el sitio de inyeccion, siendo util en la prevencion o tratamiento de una infestion de parasitos en animales.
PE2020000593A 2017-11-07 2018-11-06 Composiciones farmaceuticas inyectables de isoxazolina y usos de las mismas PE20201150A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762582381P 2017-11-07 2017-11-07
US201762608904P 2017-12-21 2017-12-21
PCT/EP2018/080226 WO2019091936A1 (en) 2017-11-07 2018-11-06 Injectable isoxazoline pharmaceutical compositions and their use against parasite infestation

Publications (1)

Publication Number Publication Date
PE20201150A1 true PE20201150A1 (es) 2020-10-26

Family

ID=74717047

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000593A PE20201150A1 (es) 2017-11-07 2018-11-06 Composiciones farmaceuticas inyectables de isoxazolina y usos de las mismas

Country Status (19)

Country Link
US (1) US20210177808A1 (es)
EP (2) EP3707128B1 (es)
JP (1) JP7269927B2 (es)
KR (2) KR102606187B1 (es)
CN (2) CN118576555A (es)
AU (2) AU2018363682B2 (es)
BR (2) BR112020008853A2 (es)
CA (1) CA3081646C (es)
CL (1) CL2020001173A1 (es)
CO (1) CO2020006257A2 (es)
DK (1) DK3707128T3 (es)
ES (1) ES2970570T3 (es)
FI (1) FI3707128T3 (es)
IL (1) IL274065B2 (es)
MX (1) MX2020004694A (es)
PE (1) PE20201150A1 (es)
PH (1) PH12020550555B1 (es)
UA (1) UA127456C2 (es)
WO (1) WO2019091936A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020004693A (es) 2017-11-07 2020-08-20 Intervet Int Bv Proceso para preparar partículas de isoxazolina de gran tamaño.
EP3934618A1 (en) * 2019-03-06 2022-01-12 Zoetis Services LLC Ready-to-use injectable formulations
US20220354828A1 (en) * 2019-10-01 2022-11-10 Shilpa Medicare Ltd Controlled release injectable ondansetron formulations
US20230310386A1 (en) * 2020-05-20 2023-10-05 Intervet Inc. Injectable pharmaceutical compositions and uses thereof
CN114306231B (zh) * 2021-12-29 2023-03-24 天津市中升挑战生物科技有限公司 一种氟雷拉纳杀虫剂及其制备方法和应用
WO2025034192A1 (en) 2023-08-07 2025-02-13 Yuriy Synytsya A water-soluble afoxolaner complex, a method for producing thereof and veterinary antiparasitic drugs comprising the same

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740421A (en) 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
KR101197482B1 (ko) 2004-03-05 2012-11-09 닛산 가가쿠 고교 가부시키 가이샤 이속사졸린 치환 벤즈아미드 화합물 및 유해생물 방제제
TW200803740A (en) 2005-12-16 2008-01-16 Du Pont 5-aryl isoxazolines for controlling invertebrate pests
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
NZ581452A (en) * 2007-06-07 2012-11-30 Kyalin Bioscience Inc Intranasal carbetocin formulations and methods for the treatment of autism
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
PL2957284T3 (pl) 2007-06-27 2018-08-31 E. I. Du Pont De Nemours And Company Sposób zwalczania szkodników zwierzęcych
TWI556741B (zh) 2007-08-17 2016-11-11 英特威特國際股份有限公司 異唑啉組成物及其作為抗寄生蟲藥上的應用
WO2009063910A1 (ja) 2007-11-12 2009-05-22 Nissan Chemical Industries, Ltd. 光学活性イソキサゾリン化合物の触媒的不斉合成方法
TWI411395B (zh) 2007-12-24 2013-10-11 Syngenta Participations Ag 殺蟲化合物
US8377942B2 (en) 2008-12-18 2013-02-19 Novartis Ag Isoxazolines derivatives and their use as pesticide
BRPI0923009B1 (pt) 2008-12-19 2018-07-17 Elanco Tiergesundheit Ag compostos de isoxazolina, composição para o controle de parasitas e uso de compostos de isoxazolina para o preparo de composição para o controle de parasitas
BRPI1011453A2 (pt) * 2009-06-24 2016-03-15 Msd Oss Bv formulacao, forma de dosagem de um medicamento, e, sal de hemipamoato de asenapina
JP5679102B2 (ja) 2009-08-03 2015-03-04 日産化学工業株式会社 ジヒドロイソキサゾール置換安息香酸化合物の光学活性体とジアステレオマー塩及びその製造方法
TWI487486B (zh) 2009-12-01 2015-06-11 Syngenta Participations Ag 以異唑啉衍生物為主之殺蟲化合物
EP3078664B1 (en) 2009-12-17 2019-02-20 Merial Inc. Antiparasitic dihydroazole compositions
EP2556060A1 (en) 2010-04-08 2013-02-13 Ah Usa 42 Llc Substituted 3,5- diphenyl-isoxazoline derivatives as insecticides and acaricides
NZ603584A (en) * 2010-05-27 2015-02-27 Du Pont Crystalline form of 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-n-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalenecarboxamide
CA2924537C (en) 2013-09-30 2018-01-16 Todd P. Foster Long-acting spiro-isoxazoline formulations
ES2971061T3 (es) * 2013-12-20 2024-06-03 Intervet Int Bv Composiciones de isoxazolina y uso de las mismas en la prevención o el tratamiento de infestaciones parasitarias en animales
UY36570A (es) * 2015-02-26 2016-10-31 Merial Inc Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
CA2981797C (en) 2015-04-08 2023-11-21 Merial, Inc. Extended release injectable formulations comprising an isoxazoline active agent, methods and uses thereof
EP3393455B1 (en) * 2015-12-22 2021-07-21 Intervet International B.V. Injectable formulation of a macrocyclic lactone and levamisole
UY37137A (es) 2016-02-24 2017-09-29 Merial Inc Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos
MX2020004693A (es) * 2017-11-07 2020-08-20 Intervet Int Bv Proceso para preparar partículas de isoxazolina de gran tamaño.
JP7558197B2 (ja) * 2019-05-03 2024-09-30 インターベット インターナショナル ベー． フェー． 注射可能な医薬組成物及びその使用

Also Published As

Publication number Publication date
FI3707128T3 (fi) 2024-03-01
CA3081646C (en) 2024-03-19
CN111295376B (zh) 2024-05-24
US20210177808A1 (en) 2021-06-17
EP4316522A2 (en) 2024-02-07
EP4316522A3 (en) 2024-04-03
CO2020006257A2 (es) 2020-05-29
RU2020117596A (ru) 2021-12-08
KR102606187B1 (ko) 2023-11-23
PH12020550555A1 (en) 2021-03-08
AU2024201169A1 (en) 2024-03-14
PH12020550555B1 (en) 2024-03-06
NZ764055A (en) 2024-07-05
CN118576555A (zh) 2024-09-03
KR20230161544A (ko) 2023-11-27
IL274065B1 (en) 2023-05-01
IL274065A (en) 2020-06-30
UA127456C2 (uk) 2023-08-30
CA3081646A1 (en) 2019-05-16
WO2019091936A1 (en) 2019-05-16
MX2020004694A (es) 2020-07-27
DK3707128T3 (da) 2024-03-18
BR122023023401A2 (pt) 2024-02-20
JP7269927B2 (ja) 2023-05-09
CN111295376A (zh) 2020-06-16
EP3707128A1 (en) 2020-09-16
EP3707128B1 (en) 2023-12-20
IL274065B2 (en) 2023-09-01
ES2970570T3 (es) 2024-05-29
KR20200085810A (ko) 2020-07-15
KR102677903B1 (ko) 2024-06-21
CL2020001173A1 (es) 2020-10-23
BR112020008853A2 (pt) 2020-10-13
AU2018363682B2 (en) 2023-11-23
AU2018363682A1 (en) 2020-05-07
JP2021501758A (ja) 2021-01-21

Similar Documents

Publication Publication Date Title
PE20201150A1 (es) Composiciones farmaceuticas inyectables de isoxazolina y usos de las mismas
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
PE20211655A1 (es) Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
UA124347C2 (uk) Циклічна динуклеотидна сполука
PE20161170A1 (es) Composiciones farmaceuticas que comprenden azd9291
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
UY37997A (es) Agentes antivirales contra la hepatitis b
UY37998A (es) Agentes antivirales contra la hepatitis b
DOP2020000023A (es) Nuevos derivados de quinolina
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
PE20200740A1 (es) Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton
PE20160608A1 (es) Compuestos de quinolina selectivamente sustituida
PE20140171A1 (es) Pirazoles fungicidas y sus mezclas
CO2020002980A2 (es) Agentes antivirales contra la hepatitis b.
PE20161206A1 (es) Derivado de urea o sal farmacologicamente aceptable del mismo
CO2020011852A2 (es) Inhibidores de canales receptores de potencial transitorio de oxadiazol
MX376106B (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infección por virus de hepatitis b.
PE20120691A1 (es) Derivados de n1-sulfonil-5-fluoropirimidinona
AR066095A1 (es) Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
PE20181074A1 (es) Compuestos heteroaromaticos como inhibidores de btk
PE20191652A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
PE20142376A1 (es) Fluormetil-5,6-dihidro-4h-[1,3]oxazinas
CO2020013876A2 (es) Nuevos derivados de quinolina